By C. Joseph Ross Daval and Aaron S. Kesselheim
October 30, 2026
In the landscape of American public health, scientific advisory committees have long served as the bedrock of credibility. These bodies—comprised of independent researchers, clinicians, and subject-matter experts—are designed to filter the complexities of modern medicine through a lens of rigorous evidence, shielding the government from the impulses of short-term political expediency. However, as of late 2026, that bedrock is crumbling.
The systematic dismantling of these committees, accelerated by the current administration, represents more than a mere bureaucratic reshuffling; it is a fundamental shift in how the United States governs its health, safety, and scientific future. By replacing consensus-driven, expert-led oversight with handpicked loyalists and opaque, ad-hoc panels, the federal government is systematically insulating itself from the very expertise required to protect the public.
The USPSTF Firings: A Pattern, Not an Anomaly
The most recent tremor in this ongoing crisis occurred in September 2026, when Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. summarily dismissed the two vice chairs of the U.S. Preventive Services Task Force (USPSTF).
Established under the Affordable Care Act, the USPSTF is a congressionally mandated body tasked with reviewing scientific evidence to determine which medical services—such as cancer screenings or cardiovascular checkups—should be covered by private insurers at no cost to patients. The law explicitly requires that these members possess "appropriate expertise" and, to the extent practicable, remain insulated from political pressure.
Secretary Kennedy’s move to remove these high-ranking officials was, in many ways, the logical conclusion of a broader, multi-year strategy to neutralize independent oversight. It follows a 2025 Supreme Court ruling, which determined that the HHS secretary holds the authority to remove committee members at will, citing a lack of statutory language restricting such termination. This judicial green light has effectively stripped these committees of their independence, leaving them vulnerable to the whims of political appointees who view scientific disagreement as an act of defiance.
A Chronology of Scientific Disengagement
The erosion of federal science is not a recent phenomenon, but its velocity has reached unprecedented levels since 2025.
- 2025: The Great Purge: The Trump administration oversaw the termination of 151 federal advisory committees across various scientific agencies, with 75 of those closures occurring within HHS alone.
- June 2025: The ACIP Overhaul: Secretary Kennedy fired the entire Advisory Committee on Immunization Practices (ACIP). This body, which had historically provided the gold-standard recommendations on vaccine safety and distribution, was replaced by a slate of appointees who, according to independent analyses, largely lack the specialized credentials in immunology and vaccinology required for the post. Many of the new members have publicly aligned themselves with the Secretary’s own skeptical views on established medical science.
- March 2026: The FDA’s Silent Retreat: The Food and Drug Administration, once the global standard for rigorous pharmaceutical review, reached a record low in convening advisory committees. In their place, the agency has increasingly relied on "expert panels"—informal, handpicked gatherings that lack the transparency and collaborative rigor of traditional advisory boards.
Supporting Data: The Cost of Ignoring Expertise
The shift from standing advisory committees to "look-alike" panels is not merely a change in format; it is a change in function. Traditional committees are characterized by long-term tenure, diverse viewpoints, and a mandate to build consensus based on the totality of existing data.
In contrast, the new "expert panels" are often assembled for a single meeting, with participants invited specifically for their perceived alignment with agency leadership. These panelists are frequently asked to share fragmented, individual analyses rather than participating in the rigorous, adversarial vetting process that defined their predecessors.
Data from the EPA, CDC, and FDA indicates that internal staffing levels have also plummeted due to targeted budget cuts and attrition. When an agency lacks internal expertise—and simultaneously destroys the external advisory networks that supplement that knowledge—the result is an information vacuum. This vacuum is inevitably filled by political, rather than scientific, decision-making.
The Role of Accountability: A Historical Case Study
To understand why this matters, one need only look at the 2021 approval of the Alzheimer’s drug aducanumab. At the time, the FDA’s own advisory committee—which included one of the authors—voted overwhelmingly against the drug’s approval. The committee highlighted contradictory efficacy data and alarming safety risks, including the prevalence of brain bleeds among participants.
Though the FDA proceeded with approval regardless, the advisory committee’s recorded, public dissent served as an anchor for the ensuing national debate. That negative vote provided the empirical grounds for journalists, Congress, and medical payors to challenge the decision. It ultimately spurred investigations that exposed the undue influence of the manufacturer on the regulatory process.
Without that public record, the FDA would have effectively operated in a vacuum. If a formal, independent advisory committee had not existed to voice its opposition, the agency could have simply pushed the drug through without a credible, expert-backed counter-narrative. By eliminating these committees, the government is not just removing an obstacle to its agenda; it is deleting the paper trail that the public uses to hold power to account.
Official Responses and the Legal Landscape
The administration’s defense of these changes rests on the principle of executive authority. Officials have argued that because advisory committees are meant to serve the agency, they must be fully aligned with the administration’s policy goals. The Supreme Court’s 2025 ruling bolstered this position, asserting that since the Secretary appoints these members, he must also retain the right to fire them to ensure the agency remains "accountable" to the President.
However, legal scholars and public health experts argue that this conflates "executive policy" with "scientific truth." Policy is the domain of the administration, but the data informing that policy must remain objective. By forcing scientific bodies to act as extensions of the executive branch, the government is essentially demanding that science be subservient to the administration’s electoral platform.
Implications for Public Trust
The implications of this shift are profound and potentially irreversible.
- Diminished Credibility: When government agencies stop listening to independent experts, the public stops trusting the government. If vaccine recommendations, cancer screening guidelines, and drug approvals are perceived as political maneuvers rather than scientific consensus, uptake will decline.
- Legislative Blindness: Congress relies on these reports to perform its oversight function. Without the foundational work of these committees, legislators are left to navigate the complexities of public health policy without a compass, forced to rely on lobbyists and biased agency reports.
- The "Expertise Gap": As top-tier scientists are purged from government roles, the talent pool for future federal service will likely dry up. Who wants to serve on a committee where their expertise is sidelined and their tenure can be terminated with a single memo?
A Call for Legislative Reform
The evisceration of scientific advice is an untenable trajectory. If the United States is to maintain its position as a leader in global health, it must act to insulate expert advice from the volatility of political cycles.
Congress possesses the tools to reverse this trend. Legislative bodies could, for instance, enact "for-cause" removal protections, ensuring that members cannot be fired simply for disagreeing with the administration’s scientific conclusions. They could implement staggered terms to ensure continuity, or even shift the appointment power to an independent, nonpartisan commission.
Such reforms would likely survive constitutional scrutiny. As the Supreme Court has noted in previous contexts, while the President holds authority over executive policy, independent scientific advisers do not exercise executive power—they exercise professional judgment. They provide the raw material of evidence upon which policy should be built.
If Congress remains committed to the principle that public policy must be guided by evidence and expertise, it must act now to restore the independence of these committees. The alternative is a future where "science" becomes whatever the sitting administration decides it is, leaving the American public to pay the price in lost health, lost trust, and lost lives.
